ATE414776T1 - Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten - Google Patents

Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten

Info

Publication number
ATE414776T1
ATE414776T1 AT02714638T AT02714638T ATE414776T1 AT E414776 T1 ATE414776 T1 AT E414776T1 AT 02714638 T AT02714638 T AT 02714638T AT 02714638 T AT02714638 T AT 02714638T AT E414776 T1 ATE414776 T1 AT E414776T1
Authority
AT
Austria
Prior art keywords
cancer
fusion proteins
autoimmune diseases
specific treatment
novel therapeutic
Prior art date
Application number
AT02714638T
Other languages
English (en)
Inventor
Mathieu Noteborn
Johan Renes
Ying-Hui Zhang
Original Assignee
Leadd Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Leadd Bv filed Critical Leadd Bv
Application granted granted Critical
Publication of ATE414776T1 publication Critical patent/ATE414776T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT02714638T 2001-03-30 2002-03-28 Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten ATE414776T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US28022901P 2001-03-30 2001-03-30

Publications (1)

Publication Number Publication Date
ATE414776T1 true ATE414776T1 (de) 2008-12-15

Family

ID=23072205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02714638T ATE414776T1 (de) 2001-03-30 2002-03-28 Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten

Country Status (9)

Country Link
US (1) US20020176860A1 (de)
EP (1) EP1377667B1 (de)
AT (1) ATE414776T1 (de)
AU (1) AU2002246455A1 (de)
DE (1) DE60229924D1 (de)
DK (1) DK1377667T3 (de)
ES (1) ES2321485T3 (de)
PT (1) PT1377667E (de)
WO (1) WO2002079222A2 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101875688B (zh) * 2010-02-10 2013-04-17 赵洪礼 重组肿瘤特异性凋亡因子制备方法中的叶酸化修饰步骤及其制品的应用
CN101921820B (zh) * 2010-02-10 2013-03-27 赵洪礼 具有活性重组肿瘤特异性凋亡因子的制备方法及其制品的应用
DK2658872T3 (da) 2010-12-27 2020-10-12 Apo T B V Polypeptid, der binder aberrerende celler og inducerer apoptose
WO2013048243A1 (en) 2011-09-29 2013-04-04 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
EP2802356A1 (de) 2012-01-13 2014-11-19 Apo-T B.V. Aberrante zelleingeschränkte immunglobuline mit einem toxischen teil

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1188832A1 (de) * 2000-09-08 2002-03-20 Leadd B.V. Verfahren zur Ablieferung der Tumor-spezifischen Apoptosis-auslösenden Aktivität von Apoptin
EP0878546A1 (de) * 1997-04-15 1998-11-18 Leadd B.V. Genabgabe-Vehikel die das Apoptosis VP2 inducierendes Protein, und/oder Apoptin exprimiert
DE69628431T2 (de) * 1995-06-07 2004-05-06 Leadd B.V. Verwendungen von apoptin
PL196605B1 (pl) * 1997-08-12 2008-01-31 Leadd Bv Sposób oznaczania zdolności transformującej, sposób oznaczania predyspozycji do przekształcania się w komórkę nowotworową, sposób oznaczania predyspozycji do dziedziczenia rodzajów raka, sposób oznaczania mutacji genu i diagnostyczny zestaw testowy
DE60003632T2 (de) * 1999-01-11 2004-04-15 Leadd B.V. Verwendung von apoptose-induzierende mittel zur herstellung eines mittels zur behandlung von (auto)immunkrankheiten
US6962696B1 (en) * 1999-10-04 2005-11-08 Vion Pharmaceuticals Inc. Compositions and methods for tumor-targeted delivery of effector molecules
EP1186665A1 (de) * 2000-09-08 2002-03-13 Leadd B.V. Verfahren zur Ablieferung der Tumor-spezifischen Apoptosis-auslösenden Aktivität von Apoptin
WO2002085305A2 (en) * 2001-04-24 2002-10-31 Washington University Compositions and methods for inducing cancer cell death

Also Published As

Publication number Publication date
EP1377667A2 (de) 2004-01-07
AU2002246455A1 (en) 2002-10-15
ES2321485T3 (es) 2009-06-08
US20020176860A1 (en) 2002-11-28
DK1377667T3 (da) 2009-03-30
EP1377667B1 (de) 2008-11-19
WO2002079222A3 (en) 2003-05-08
DE60229924D1 (de) 2009-01-02
WO2002079222A2 (en) 2002-10-10
PT1377667E (pt) 2009-03-13

Similar Documents

Publication Publication Date Title
EP1194164B8 (de) Prion protein peptide und deren verwendung
AU2002305450A1 (en) Proteomimetic compounds and methods
DE60039752D1 (de) Herstellung tetravalenter antikörper
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
MY136095A (en) Use of human anti-ctla-4 antibodies for treatment of cancer
DK1368060T3 (da) HMGB1-proteininhibitorer og/eller antagonister til behandlingen af vaskulære sygdomme
ATE314095T1 (de) Virusähnliche partikel zur induktion von autoantikörpern
TR200102191T2 (tr) HER-2/neu füzyon proteinleri.
MY150237A (en) Cripto blocking antibodies and uses thereof
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
ATE242633T1 (de) Dialkylfumarate zur behandlung von autoimmunerkrankungen
ATE507839T1 (de) Kombinationstherapie
ATE281180T1 (de) Pharmazeutische zusammensetzung enthaltend nicht- mhc-abhängige t-zellen/nk-zellen und mhc- abhängige zellen zur behandlung von tumoren
MA27880A1 (fr) Derives de tetrahydrocarbazole et leur utilisation pharmaceutique
DE60204224D1 (de) Verwendung bestimmter substituierter pyrrolidone wie z.b. piracetam bei der behandlung von viralen und anderen erkrankungen
DE60215649D1 (de) Zusammensetzungen und verfahren zur behandlung von hyperimmunreaktionen im auge
DE60229924D1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten
ATE313561T1 (de) Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen
ATE310828T1 (de) Implantat und vektor zur behandlung von erworbenen krankheiten
WO2001007479A3 (en) Fragments of cellular prion protein and methods useful in the diagnosis and treatment of prion diseases
AU2001235761A1 (en) Diagnosis of breast cancer using bcmp-11 as marker
DE69835828D1 (de) Muc-1 derivate und deren verwendung zur behandlung von krebsassoziierter muc-1 mucin induzierter immunosuppression
ATE481475T1 (de) Immunmodulation mit rezeptorinduziertem tod durch apoptosis
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1377667

Country of ref document: EP

REN Ceased due to non-payment of the annual fee